|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Lee JO, Kim DY, Lim JH, et al: Palliative
chemotherapy for patients with recurrent hepatocellular carcinoma
after liver transplantation. J Gastroenterol Hepatol. 24:800–805.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tomuleasa C, Soritau O, Fischer-Fodor E,
et al: Arsenic trioxide plus cisplatin/interferon
alpha-2b/doxorubicin/capecitabine combination chemotherapy for
unresectable hepatocellular carcinoma. Hematol Oncol Stem Cell
Ther. 4:60–66. 2011. View Article : Google Scholar
|
|
4
|
Walsh N, Larkin A, Kennedy S, et al:
Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and
ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol. 9:62009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shi H, Lu D, Shu Y, Shi W, Lu S and Wang
K: Expression of multidrug-resistance-related proteins
P-glycoprotein, glutathione-S-transferases, topoisomerase-II and
lung resistance protein in primary gastric cardiac adenocarcinoma.
Cancer Invest. 26:344–351. 2008. View Article : Google Scholar
|
|
6
|
Mansilla S, Rojas M, Bataller M, Priebe W
and Portugal J: Circumvention of the multidrug-resistance protein
(MRP-1) by an antitumor drug through specific inhibition of gene
transcription in breast tumor cells. Biochem Pharmacol. 73:934–942.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Filomeni G, Turella P, Dupuis ML, et al:
6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol, a specific
glutathione S-transferase inhibitor, overcomes the multidrug
resistance (MDR)-associated protein 1-mediated MDR in small cell
lung cancer. Mol Cancer Ther. 7:371–379. 2008. View Article : Google Scholar
|
|
8
|
Ronaldson PT, Ashraf T and Bendayan R:
Regulation of multidrug resistance protein 1 by tumor necrosis
factor alpha in cultured glial cells: involvement of nuclear
factor-kappaB and c-Jun N-terminal kinase signaling pathways. Mol
Pharmacol. 77:644–659. 2010. View Article : Google Scholar
|
|
9
|
Liu B, Qu L and Tao H: Cyclo-oxygenase 2
up-regulates the effect of multidrug resistance. Cell Biol Int.
34:21–25. 2010.PubMed/NCBI
|
|
10
|
Ma J, Dong C and Ji C: MicroRNA and drug
resistance. Cancer Gene Ther. 17:523–531. 2010. View Article : Google Scholar
|
|
11
|
Feng DD, Zhang H, Zhang P, et al:
Down-regulated miR-331-5p and miR-27a are associated with
chemotherapy resistance and relapse in leukaemia. J Cell Mol Med.
15:2164–2175. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kovalchuk O, Filkowski J, Meservy J, et
al: Involvement of microRNA-451 in resistance of the MCF-7 breast
cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther.
7:2152–2159. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liang Z, Wu H, Xia J, et al: Involvement
of miR-326 in chemotherapy resistance of breast cancer through
modulating expression of multidrug resistance-associated protein 1.
Biochem Pharmacol. 79:817–824. 2010. View Article : Google Scholar
|
|
14
|
Xia L, Zhang D, Du R, et al: miR-15b and
miR-16 modulate multidrug resistance by targeting BCL2 in human
gastric cancer cells. Int J Cancer. 123:372–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu Y, Xia F, Ma L, et al: MicroRNA-122
sensitizes HCC cancer cells to adriamycin and vincristine through
modulating expression of MDR and inducing cell cycle arrest. Cancer
Lett. 310:160–169. 2011.PubMed/NCBI
|
|
16
|
Zhao X, Yang L, Hu J and Ruan J: miR-138
might reverse multidrug resistance of leukemia cells. Leuk Res.
34:1078–1082. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao X, Yang L and Hu J: Down-regulation
of miR-27a might inhibit proliferation and drug resistance of
gastric cancer cells. J Exp Clin Cancer Res. 30:552011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu W, Shan X, Wang T, Shu Y and Liu P:
miR-181b modulates multidrug resistance by targeting BCL2 in human
cancer cell lines. Int J Cancer. 127:2520–2529. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Akao Y, Noguchi S, Iio A, Kojima K, Takagi
T and Naoe T: Dysregulation of microRNA-34a expression causes
drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer
Lett. 300:197–204. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bai H, Xu R, Cao Z, Wei D and Wang C:
Involvement of miR-21 in resistance to daunorubicin by regulating
PTEN expression in the leukaemia K562 cell line. FEBS Lett.
585:402–408. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang H, Kong W, He L, et al: MicroRNA
expression profiling in human ovarian cancer: miR-214 induces cell
survival and cisplatin resistance by targeting PTEN. Cancer Res.
68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pan YZ, Morris ME and Yu AM: MicroRNA-328
negatively regulates the expression of breast cancer resistance
protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol.
75:1374–1379. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhong X, Xiong M, Meng X and Gong R:
Comparison of the multi-drug resistant human hepatocellular
carcinoma cell line Bel-7402/ADM model established by three
methods. J Exp Clin Cancer Res. 29:1152010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hummel R, Hussey DJ and Haier J:
MicroRNAs: predictors and modifiers of chemo- and radiotherapy in
different tumour types. Eur J Cancer. 46:298–311. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sorrentino A, Liu CG, Addario A, Peschle
C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant
ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Galluzzi L, Morselli E, Vitale I, et al:
miR-181a and miR-630 regulate cisplatin-induced cancer cell death.
Cancer Res. 70:1793–1803. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dai Y, Xie CH, Neis JP, Fan CY, Vural E
and Spring PM: MicroRNA expression profiles of head and neck
squamous cell carcinoma with docetaxel-induced multidrug
resistance. Head Neck. 33:786–791. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu ZW, Zhong LP, Ji T, Zhang P, Chen WT
and Zhang CP: MicroRNAs contribute to the chemoresistance of
cisplatin in tongue squamous cell carcinoma lines. Oral Oncol.
46:317–322. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Boni V, Bitarte N, Cristobal I, et al:
miR-192/miR-215 influence 5-fluorouracil resistance through cell
cycle-mediated mechanisms complementary to its post-transcriptional
thymidilate synthase regulation. Mol Cancer Ther. 9:2265–2275.
2010. View Article : Google Scholar
|
|
30
|
Pogribny IP, Filkowski JN, Tryndyak VP,
Golubov A, Shpyleva SI and Kovalchuk O: Alterations of microRNAs
and their targets are associated with acquired resistance of MCF-7
breast cancer cells to cisplatin. Int J Cancer. 127:1785–1794.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chang CJ, Hsu CC, Chang CH, et al: Let-7d
functions as novel regulator of epithelial-mesenchymal transition
and chemoresistant property in oral cancer. Oncol Rep.
26:1003–1010. 2011.PubMed/NCBI
|
|
32
|
Salter KH, Acharya CR, Walters KS, et al:
An integrated approach to the prediction of chemotherapeutic
response in patients with breast cancer. PLoS One. 3:e19082008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen L, Li H, Han L, et al: Expression and
function of miR-27b in human glioma. Oncol Rep. 26:1617–1621.
2011.PubMed/NCBI
|
|
34
|
Ji J, Zhang J, Huang G, Qian J, Wang X and
Mei S: Over-expressed microRNA-27a and 27b influence fat
accumulation and cell proliferation during rat hepatic stellate
cell activation. FEBS Lett. 583:759–766. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee JJ, Drakaki A, Iliopoulos D and Struhl
K: MiR-27b targets PPARgamma to inhibit growth, tumor progression
and the inflammatory response in neuroblastoma cells. Oncogene.
31:3818–3825. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang Y, Rathinam R, Walch A and Alahari
SK: ST14 (suppression of tumorigenicity 14) gene is a target for
miR-27b, and the inhibitory effect of ST14 on cell growth is
independent of miR-27b regulation. J Biol Chem. 284:23094–23106.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bhaumik D, Scott GK, Schokrpur S, et al:
MicroRNAs miR-146a/b negatively modulate the senescence-associated
inflammatory mediators IL-6 and IL-8. Aging (Albany, NY).
1:402–411. 2009.PubMed/NCBI
|
|
38
|
Chatzikyriakidou A, Voulgari PV, Georgiou
I and Drosos AA: The role of microRNA-146a (miR-146a) and its
target IL-1R-associated kinase (IRAK1) in psoriatic arthritis
susceptibility. Scand J Immunol. 71:382–385. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bhaumik D, Scott GK, Schokrpur S, Patil
CK, Campisi J and Benz CC: Expression of microRNA-146 suppresses
NF-kappaB activity with reduction of metastatic potential in breast
cancer cells. Oncogene. 27:5643–5647. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hurst DR, Edmonds MD, Scott GK, Benz CC,
Vaidya KS and Welch DR: Breast cancer metastasis suppressor 1
up-regulates miR-146, which suppresses breast cancer metastasis.
Cancer Res. 69:1279–1283. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kogo R, Mimori K, Tanaka F, Komune S and
Mori M: Clinical significance of miR-146a in gastric cancer cases.
Clin Cancer Res. 17:4277–4284. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gao W, Yu Y, Cao H, et al: Deregulated
expression of miR-21, miR-143 and miR-181a in non small cell lung
cancer is related to clinicopathologic characteristics or patient
prognosis. Biomed Pharmacother. 64:399–408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Schwind S, Maharry K, Radmacher MD, et al:
Prognostic significance of expression of a single microRNA,
miR-181a, in cytogenetically normal acute myeloid leukemia: a
Cancer and Leukemia Group B study. J Clin Oncol. 28:5257–5264.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang XF, Shi ZM, Wang XR, et al: MiR-181d
acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2.
J Cancer Res Clin Oncol. 138:573–584. 2012. View Article : Google Scholar : PubMed/NCBI
|
